Phathom Pharmaceuticals PHAT

$ 7.45 -4.73%

Quarterly report 2024-Q3
added 11-07-2024

Phathom Pharmaceuticals Balance Sheet 2011-2024 | PHAT

Annual Balance Sheet Phathom Pharmaceuticals

	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-243 M	-59.4 M	-93.1 M	-241 M	-220 M	1.07 M	-	-	-	-	-	-	-
Long Term Debt	138 M	95.3 M	89.7 M	39.6 M	22.8 M	-	-	-	-	-	-	-	-
Long Term Debt Current	726 K	708 K	487 K	474 K	161 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	45.3 M	25.5 M	-	-	-	-	-	-	-	-
Total Current Liabilities	38.8 M	26.2 M	18.9 M	55.5 M	3.75 M	-	-	-	-	-	-	-	-
Total Liabilities	487 M	240 M	117 M	101 M	29.2 M	2.19 M	-	-	-	-	-	-	-
Deferred Revenue	7.11 M	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-929 M	-727 M	-529 M	-385 M	-256 M	-1.29 M	-	-	-	-	-	-	-
Total Assets	414 M	165 M	189 M	295 M	257 M	902 K	-	-	-	-	-	-	-
Cash and Cash Equivalents	381 M	155 M	183 M	287 M	244 M	-	-	-	-	-	-	-	-
Book Value	-72.8 M	-74.8 M	72.2 M	194 M	228 M	-1.29 M	-	-	-	-	-	-	-
Total Shareholders Equity	-72.8 M	-74.8 M	72.2 M	194 M	228 M	-1.29 M	-	-	-	-	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Phathom Pharmaceuticals

	2024-Q3	2024-Q2	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	176 M	174 M	138 M	99.3 M	97.8 M	96.6 M	95.3 M	93.9 M	-	91 M	89.7 M	88.3 M	37.3 M	35.6 M	39.6 M	39.6 M	39.6 M	39.6 M	22.8 M	22.8 M	22.8 M	635 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	574 M	553 M	487 M	255 M	247 M	234 M	240 M	228 M	-	111 M	117 M	125 M	82.5 M	82 M	101 M	101 M	101 M	101 M	29.2 M	29.2 M	29.2 M	29.2 M	2.19 M	2.19 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	20.2 M	9.91 M	7.11 M	2.39 M	276 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.19 B	-1.1 B	-929 M	-849 M	-806 M	-765 M	-727 M	-672 M	-	-570 M	-529 M	-494 M	-457 M	-420 M	-385 M	-385 M	-385 M	-385 M	-256 M	-256 M	-256 M	-256 M	-1.29 M	-1.29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	387 M	319 M	414 M	237 M	265 M	144 M	165 M	202 M	-	149 M	189 M	228 M	215 M	246 M	295 M	295 M	295 M	295 M	257 M	257 M	257 M	257 M	902 K	902 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	335 M	276 M	381 M	214 M	249 M	130 M	155 M	197 M	-	138 M	183 M	225 M	210 M	238 M	287 M	287 M	287 M	287 M	244 M	244 M	244 M	244 M	879 K	879 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Book Value	-187 M	-234 M	-72.8 M	-17.8 M	17.6 M	-90.2 M	-74.8 M	-26.4 M	-	38 M	72.2 M	103 M	132 M	164 M	194 M	194 M	194 M	194 M	228 M	228 M	228 M	228 M	-1.29 M	-1.29 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-187 M	-234 M	-72.8 M	-17.8 M	17.6 M	-90.2 M	-74.8 M	-26.4 M	-7 M	38 M	72.2 M	103 M	132 M	164 M	194 M	194 M	194 M	194 M	228 M	228 M	228 M	228 M	-1.29 M	-1.29 M	-512 K	-252 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency